Skip to main content

Table 2 Costs estimated for a three-month period (one Markov model cycle) of each health state of the model, in Brazilian real (BRL) and percentage (%) by category in strategy 2 (XELOX plus bevacizumab)

From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Categories First-line treatment (XELOX plus bevacizumab) Second-line treatment (FOLFIRI) Clinical Support Death
R$ % R$ % R$ % R$ %
Medications 27,592.00 89.57 4327.80 33.33 0.00 0.00 0.00 0.00
Preparation (Pharmacy) 120.08 0.39 270.18 2.08 0.00 0.00 0.00 0.00
Administration (Nursing) 1006.40 3.27 6700.74 51.61 0.00 0.00 0.00 0.00
Laboratory tests 367.00 1.19 409.08 3.15 265.48 5.28 0.00 0.00
Imaging tests 1720.00 5.58 1276.20 9.83 0.00 0.00 0.00 0.00
Hospitalization 0.00 0.00 0.00 0.00 4767.03 94.72 0.00 0.00
Total 30,805.48 100.00 12,984.00 100.00 5032.51 100.00 0.00 0.00
  1. Abbreviations: XELOX Xeloda® and oxaliplatin, FOLFIRI 5-fluorouracil, leucovorin and irinotecan